LDX — Lumos Diagnostics Holdings Share Price
0.000.00%
Last trade - 00:00- AU$15.40m
- AU$26.12m
- $10.54m
- 16
- 56
- 44
- 34
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.14 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.28 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -53.34% | ||
| Return on Equity | -87.62% | ||
| Operating Margin | -109.41% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.56 | 5.63 | 18.85 | 11.63 | 10.54 | 10.76 | 13.28 | 39.29% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lumos Diagnostics Holdings Ltd is an Australia-based company, which specializes in point-of-care (POC) diagnostic test technology to help healthcare professionals diagnose and manage medical conditions. The Company offers customized assay development and manufacturing services for POC tests and digital reader platforms. It also directly develops, manufactures, and commercializes, Lumos-branded POC tests that target infectious and inflammatory diseases. The Company’s products include FEBRIDX, COVIDX, and ViraDx. FebriDx is a point-of-care test which can be used to detect and aid in differentiating bacterial from viral acute respiratory infections. ViraDx is a point-of-care, three-in-one COVID-19/Flu A/Flu B rapid antigen test. Its services include assay development, reader development, cloud and data, and manufacturing. It manages the full development program for point-of-care (POC) assays, from sourcing and/or generation of reagents, right through to verification and validation.
Directors
- Samuel Lanyon CHM
- Robert Sambursky CEO
- Lawrence Mehren NVC (53)
- Melanie Leydin CFO
- Tracy Weimar SEC
- Bronwyn Le Grice NED
- Catherine Robson NED
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 7th, 2018
- Public Since
- July 5th, 2021
- No. of Shareholders
- 1,129
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 481,300,042
- Address
- 100 Albert Rd, Level 4, SOUTH MELBOURNE, 3205
- Web
- https://lumosdiagnostics.com/
- Phone
- +61 390871598
- Auditors
- William Buck Audit (Vic) Pty Ltd
Upcoming Events for LDX
Similar to LDX
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Allegra Medical Technologies
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
FAQ
What is the Lumos Diagnostics Holdings share price?
As of Today at 21:53 UTC, shares in Lumos Diagnostics Holdings are trading at AU$0.03. This share price information is delayed by 15 minutes.
How has the Lumos Diagnostics Holdings share price performed this year?
Shares in Lumos Diagnostics Holdings last closed at AU$0.03 and the price had moved by +175% over the past 365 days. In terms of relative price strength the Lumos Diagnostics Holdings share price has outperformed the ASX All Ordinaries Index by +150.48% over the past year.
What are the analyst and broker recommendations for Lumos Diagnostics Holdings?
The overall consensus recommendation for Lumos Diagnostics Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Lumos Diagnostics Holdings dividend yield?
Lumos Diagnostics Holdings does not currently pay a dividend.
Does Lumos Diagnostics Holdings pay a dividend?
Lumos Diagnostics Holdings does not currently pay a dividend.
When does Lumos Diagnostics Holdings next pay dividends?
Lumos Diagnostics Holdings does not currently pay a dividend.
How do I buy Lumos Diagnostics Holdings shares?
To buy shares in Lumos Diagnostics Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lumos Diagnostics Holdings?
As of the previous close price of AU$0.03, shares in Lumos Diagnostics Holdings had a market capitalisation of AU$15.88m.
Where are Lumos Diagnostics Holdings shares listed?
Here are the trading details for Lumos Diagnostics Holdings:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: LDX
What kind of share is Lumos Diagnostics Holdings?
Based on an overall assessment of its quality, value and momentum Lumos Diagnostics Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lumos Diagnostics Holdings share price forecast for 2024?
The analyst consensus target price for shares in Lumos Diagnostics Holdings is AU$0.06. That is 81.82% above the last closing price of AU$0.03.
Analysts covering Lumos Diagnostics Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$0.00 for the next financial year.
What is the trend in the Lumos Diagnostics Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lumos Diagnostics Holdings. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -53.91%.
As of the last closing price of AU$0.03, shares in Lumos Diagnostics Holdings were trading -52.82% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lumos Diagnostics Holdings PE Ratio?
The Lumos Diagnostics Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lumos Diagnostics Holdings?
Lumos Diagnostics Holdings' management team is headed by:
- Samuel Lanyon - CHM
- Robert Sambursky - CEO
- Lawrence Mehren - NVC
- Melanie Leydin - CFO
- Tracy Weimar - SEC
- Bronwyn Le Grice - NED
- Catherine Robson - NED